---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-25-000108"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:30:19.890923+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "medium"
source: SEC EDGAR
---

# Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial

## Summary
- Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.
- Phase 1 trial ongoing in patients with relapsed/refractory B cell malignancies.
- Investor presentation dated September 3, 2025, furnished as Exhibit 99.1.
- Specific clinical data updates not detailed in the 8-K filing text.

## SEC filing metadata
- accession: 0001549595-25-000108
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/0001549595-25-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959525000108/nrix-20250903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-25-000108
- JSON: https://secwatch.observer/filing/0001549595-25-000108.json
- Plain text: https://secwatch.observer/filing/0001549595-25-000108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.